Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.12 USD
Change Today -0.0001 / -0.08%
Volume 11.2K
As of 8:10 PM 10/2/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

135 Beaver Street

Waltham, MA 02452

United States

Phone: 781-398-0700

Fax: 781-398-0720

Interleukin Genetics, Inc., a molecular diagnostics company, develops and commercializes genetic tests to guide prevention and treatment of chronic diseases of aging. The company’s business focuses on personalized health, by providing genetic tests that are actionable and provide clinical value. The company’s tests are made available through healthcare providers, or for some of its tests, directly to end users. The company has patents covering the use of specific patterns of gene variations for various common chronic diseases. The company’s genetic tests that are being commercialized are: PerioPredict: This test analyzes patterns of genetic variations that change the biology to amplify inflammatory responses of individuals who carry these genetic patterns. The test identifies individuals who are at increased risk for more severe periodontal disease and disease progression, and require more preventive care. In 2013, the company announced the introduction of PerioPredict, its next-generation version of the PST genetic test. The genetic test utilizes an expansion of previous genetic markers that cover all major ethnic groups. The company no longer offers the PST genetic test. Weight Management Genetic Test: This test determines whether individuals would lose weight more predictably on a low fat, low carbohydrate or balanced diet and whether normal or vigorous exercise is needed to most efficiently lose existing body fat. This test is marketed under the company’s Inherent Health brand. The test results guide more effective long term weight loss. Bone Health Genetic Test: This test is designed to identify whether an individual is more likely to be susceptible to spine fractures and low bone mineral density associated with osteoporosis. This test is marketed under the company’s Inherent Health brand. Heart Health Genetic Test: This test is designed to identify genetic predisposition to excess inflammation, which is a risk factor for heart attack. This test is marketed under the company’s Inherent Health brand. Nutritional Needs Genetic Test: This test is designed to identify DNA variations in genes crucial to B-vitamin metabolism and the ability to manage oxidative stress. This test is marketed under the company’s Inherent Health brand. Wellness Select Genetic Test: This allows buyers to purchase any combination of Inherent Health genetic tests at a discounted price. This is marketed under the company’s Inherent Health brand. The company has an amended and restated preferred participation agreement with Renaissance Health Services Corporation (RHSC), the exclusive distributor of the Delta Dental brand in eight states, with respect to reimbursement for the company’s PerioPredict test. The company markets its Inherent Health brand of genetic assessment tests primarily through its commercial relationships with Alticor affiliated companies, such as Amway. In addition to the marketed genetic tests, the company has developed an Osteoarthritis (OA) genetic test to identify individuals at increased risk for progression of OA and its complications, such as knee replacement; and a cardiovascular disease (CVD) test to identify individuals at increased risk for a second heart attack. In early 2015, the company entered into an arrangement with Isis Pharmaceuticals, Inc. pursuant to which the company is providing testing services to support Isis clinical trials. The company is exploring additional opportunities to collaborate on drug clinical trials, and to expand the use of its genetic tests in clinical practice. The company has focused its research, development and commercialization efforts on identifying combinations of SNP variations that alter biology involved in inflammation or metabolic disease. It has worked with various universities throughout the world to identify genetic variations that influence the body’s inflammatory response. As of December 31, 2014, some of the company’s clinical research collaborations included studies at Stanford University; the University of North Carolina at Chapel Hill; the Mayo Clinic; Brigham & Women’s Hospital (Harvard Medical School); University of California at San F

Page 12Next Page

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ILIU:US $0.12 USD -0.0001

ILIU Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ILIU.
View Industry Companies

Industry Analysis


Industry Average

Valuation ILIU Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTERLEUKIN GENETICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at